TY - JOUR
T1 - RS 86 in the treatment of alzheimer's disease
T2 - Cognitive and biological effects
AU - Hollander, Eric
AU - Davidson, Michael
AU - Mohs, Richard C.
AU - Horvath, Thomas B.
AU - Davis, Bonnie M.
AU - Zemishlany, Zvi
AU - Davis, Kenneth L.
N1 - Funding Information:
From the Psychiatry Service. Bronx VA Medical Center, and the Departments of Psychiatry and Pharmacology, Mount Stnal School of Medicine, Bronx, NY. Supported by Program Project Granl AGO2219 and Alzheimer’s Disease Research Center Grant AC-O.5138 from the National Instttute on Aging and by the Medical Research Service of the Veterans Administration. Address reprmt requests to Dr. Kenneth L. Davis. Department of Psychiatry (I 16A), Bronx VA Medical Center. I30 West Kingsbridge Road, Bronx, NY 10468. Received September 20, 1986; rewed January 2. 1987.
PY - 1987/9
Y1 - 1987/9
N2 - Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38% increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.
AB - Twelve patients who met Research Diagnostic Criteria for Alzheimer's disease (AD) completed a double-blind crossover study comparing oral RS 86, a long-acting and specific muscarinic agonist, with placebo. Cognitive and noncognitive effects were assessed with the Alzheimer's Disease Assessment Scale (ADAS). RS 86 was found to improve ADAS test scores consistently (both cognitive and noncognitive subscales) in seven patients, with a clinically obvious improvement in only two patients. RS 86 produced a significant increase in peak nocturnal cortisol levels, and this increase correlated with improvement on ADAS testing. Similarly, there was a 38% increase in amplitude of the P300 evoked potential with RS 86. The biological findings suggest that RS 86 was effective only to the extent that it enhanced central cholinergic activity.
UR - http://www.scopus.com/inward/record.url?scp=0023261008&partnerID=8YFLogxK
U2 - 10.1016/0006-3223(87)90049-7
DO - 10.1016/0006-3223(87)90049-7
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0023261008
SN - 0006-3223
VL - 22
SP - 1067
EP - 1078
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 9
ER -